Accueil>>Signaling Pathways>> Immunology/Inflammation>> FKBP>>AP20187

AP20187 (Synonyms: B/B Homodimerizer)

Catalog No.GC14498

AP20187 (B/B Homodimerizer) est un ligand perméable aux cellules utilisé pour dimériser les protéines de fusion de la protéine de liaison FK506 (FKBP) et initier des cascades de signalisation biologique et l'expression génique ou perturber les interactions protéine-protéine.

Products are for research use only. Not for human use. We do not sell to patients.

AP20187 Chemical Structure

Cas No.: 195514-80-8

Taille Prix Stock Qté
1mg
87,00 $US
En stock
10mg
344,00 $US
En stock
5mg
216,00 $US
En stock
10mM (in 1mL DMSO)
561,00 $US
En stock
25mg
672,00 $US
En stock
50mg
1 040,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

AP20187 is a small dimerizer drug [1].

To solve the graft-versus-host disease, the in vivo behavior of the transplanted cells should be controlled. AP20187 is used in the conditional system as a chemical inducer of dimerization (CID). Another component is a fusion protein. The CIDs have advantages in gene therapy, it offers the possibility of achieving selection without the toxic effects. In vivo studies show that AP20187 can produces a notable expansion of transduced red cells, platelets, and to a lesser extent, granulocytes [1].

AP20187 is also reported to be used in an AP20187–LFv2IRE system. In this system, AP20187 administration causes the activation of LFv2IRE and results in increased uptake of both hepatic glycogen content and muscular glucose [2].

References:
[1] Neff T, Blau CA. Pharmacologically regulated cell therapy. Blood. 2001 May 1;97(9):2535-40.
[2] Cotugno G, Formisano P, Giacco F, Colella P, Beguinot F, Auricchio A. AP20187-mediated activation of a chimeric insulin receptor results in insulin-like actions in skeletal muscle and liver of diabetic mice. Hum Gene Ther. 2007 Feb;18(2):106-17.

Avis

Review for AP20187

Average Rating: 5 ★★★★★ (Based on Reviews and 40 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AP20187

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.